Back to today’s briefing

Story perspectives

Repatha's Success: $2.2B Sales Amid Heart Disease Breakthrough

10/2/2025

31 5

Summary

Story summary

Repatha (Amgen's cholesterol drug) reduced cardiovascular events in a 12,000-patient trial.
In patients without prior heart disease, Repatha can prevent events.
2024 sales reached $2.2 billion, up 36% from 2023, still below earlier projections.
The FDA expanded primary-prevention approval for high-risk patients. Analysts expect limited near-term sales growth amid Inflation Reduction Act price controls and competition from oral PCSK9 inhibitors.

1 of 1

Story summary

Repatha (Amgen's cholesterol drug) reduced cardiovascular events in a 12,000-patient trial.
In patients without prior heart disease, Repatha can prevent events.
2024 sales reached $2.2 billion, up 36% from 2023, still below earlier projections.
The FDA expanded primary-prevention approval for high-risk patients. Analysts expect limited near-term sales growth amid Inflation Reduction Act price controls and competition from oral PCSK9 inhibitors.